Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World data on ripretinib for advanced GIST: what does it mean for patients?

NCT ID NCT06619275

Knowledge-focused Sponsor: iOMEDICO AG Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed observational study in Germany followed 10 patients with advanced gastrointestinal stromal tumor (GIST) who had already tried three or more prior treatments. Researchers tracked how ripretinib affected their quality of life and disease control in everyday clinical practice. The goal was to gather real-world information on the drug's benefits and safety outside of a controlled trial setting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ripretinib (a kinase inhibitor drug)
What this could lead to
If successful, this study could provide real-world evidence on how ripretinib affects quality of life and disease control in advanced GIST patients.
What could go wrong
This is a small observational study (10 participants) with no control group, so results may not apply broadly. It does not test a new treatment, only observes routine care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

10 people

The number who actually took part.

Started

Oct 2024

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients diagnosed with advanced GIST who received 3 or more tyrosine kinase inhibitors (including imatinib).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patient is eligible if all criteria are met: * Aged 18 years or older. * Histologically confirmed advanced GIST. * Patients must have received prior treatment with three or more kinase inhibitors, including imatinib. * Decision for treatment with ripretinib as per current SmPC. * Signed written informed consent \* Patients are allowed to be enrolled up to 6 weeks after their first dose of ripretinib. Patients with signed written informed consent after start of ripretinib treatment are not participating in the PRO assessments. * Willingness and capability to participate in Patient-Reported Outcome (PRO) assessment in German language. * Other criteria according to current SmPC. Exclusion Criteria: * Participation in an interventional clinical trial within 30 days prior to enrolment or simultaneous participation in an interventional clinical trial except for the follow-up period. * Patients unable to consent. * Other contraindications according to current SmPC.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gist - gastrointestinal stromal tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastrointestinal stromal tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gist - gastrointestinal stromal tumor

Contacts and locations

Locations

  • Praxis für interdisziplinäre Onkologie und Hämatologie

    Freiburg im Breisgau, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.